Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 561 to 570 of 2591 total matches.
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
, and various cancers.1
AVAILABILITY — Ashwagandha is available commercially
in tablets, capsules, liquid ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
thromboembolic pulmonary hypertension,
was the first.1
Pronunciation Key
Vericiguat: ver” i sig’ ue at Verquvo ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
are thought to be caused by degeneration of
other neurotransmitter systems.1,2 No disease-modifying
drugs ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
in blister packs; a new inhaler should be used with each new carton
84 mg inhaled 1-5x/day prn
iFDA ...
View the Comparison Table: Drugs for Parkinson's Disease
Twirla - A New Contraceptive Patch
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
hormonal
contraceptives. Unscheduled bleeding/spotting lasting
≥1 day occurred in 60.4% of women in cycle ...
The FDA has approved Twirla (Agile Therapeutics),
a transdermal contraceptive patch containing the
estrogen ethinyl estradiol and the progestin
levonorgestrel, for use in women with a BMI <30 kg/m2.
It is the second contraceptive patch to become
available in the US; Xulane, a patch that delivers
ethinyl estradiol and the progestin norelgestromin,
has been available since 2014.
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
; it has not been compared to first-line
treatments.1 A sodium oxybate oral solution (Xyrem)
and a mixed-salt oxybate oral ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Osilodrostat (Isturisa) for Cushing's Disease
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
for coronary artery disease, stroke,
venous thromboembolism, and serious infections.1
STANDARD TREATMENT ...
The FDA has approved osilodrostat (Isturisa –
Recordati), a cortisol synthesis inhibitor, for oral
treatment of adults with Cushing's disease when
surgical resection of the pituitary adenoma is not an
option or has not been curative. Osilodrostat is the
first cortisol synthesis inhibitor to be approved in
the US for this indication. Other oral steroidogenesis
inhibitors such as ketoconazole and metyrapone have
been used off-label for this indication for many years.
Avapritinib (Ayvakit) for GIST
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
mutations.1 The PDGFRA
D842V mutation is the most common exon 18
mutation.
The oral tyrosine kinase ...
The FDA has approved the oral tyrosine kinase
inhibitor avapritinib (Ayvakit – Blueprint Medicines)
for treatment of unresectable or metastatic gastrointestinal
stromal tumors (GISTs) harboring a
platelet-derived growth factor receptor alpha
(PDGFRA) D842V or other PDGFRA exon 18 mutation.
Avapritinib is the first drug to be approved for this
indication in the US.
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
months), and an optimal sequence of treatment has
not been established.1,2
Some patients with advanced ...
The FDA has approved sacituzumab govitecan-hziy
(Trodelvy – Immunomedics), a trophoblast cell-surface
antigen-2 (Trop-2)-directed antibody and topoisomerase
inhibitor conjugate, for treatment of adults with metastatic
triple-negative breast cancer who have received ≥2 prior
therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
Thoracic Society and the Infectious Diseases Society
of America (ATS/IDSA) were updated in 2019.1 ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.